Danaher Corporation $DHR Stock: Enclave Advisors LLC Boosts Holdings

Enclave Advisors LLC raised its position in Danaher Corporation (NYSE:DHR) by 104.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,102 shares of the conglomerate’s stock after purchasing an additional 2,612 shares during the quarter. Enclave Advisors LLC’s holdings in Danaher were worth $1,130,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. BlackRock Inc. purchased a new position in shares of Danaher in the second quarter valued at approximately $10,492,520,000. Jupiter Topco LLC purchased a new position in shares of Danaher during the second quarter worth about $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the second quarter valued at approximately $1,287,949,000. Bank of America Corp DE purchased a new stake in Danaher in the 2nd quarter valued at $993,846,000. Finally, Legal & General Group Plc acquired a new stake in shares of Danaher during the second quarter worth about $801,056,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.9%

DHR stock opened at $223.30 on Wednesday. The company has a market cap of $156.98 billion, a price-to-earnings ratio of 39.66, a PEG ratio of 2.78 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The business has a fifty day simple moving average of $212.41 and a 200-day simple moving average of $195.13. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.77 earnings per share. On average, equities research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is currently 28.42%.

Analysts Set New Price Targets

Several brokerages have issued reports on DHR. Evercore reissued an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Morgan Stanley lifted their price target on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research note on Monday. Royal Bank Of Canada upped their target price on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Finally, Barclays upped their price objective on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.